The type III TGF-β receptor suppresses breast cancer progression
J. Clin. Invest. Mei Dong, et al. 117:206 doi:10.1172/JCI29293 [Go to this article.]

Figure 6
TβRIII inhibits tumor angiogenesis without altering cancer cell proliferation and apoptosis in vivo. (A) Tissue sections of primary tumors and lung metastases from mice implanted with 4T1-Neo and 4T1-TβRIII cells were immunostained for PCNA and TUNEL to evaluate cell proliferation and apoptosis, respectively. Representative staining frequency and intensity is shown (original magnification, ×40). (B) Immunostaining of CD31 (original magnification, ×10) was performed as a marker to evaluate angiogenesis. Note the decreased number and size of tumor-associated blood vessels as well as decreased staining intensity (insets; original magnification, ×100) in 4T1-TβRIII primary tumors and lung metastases. Values are the averages from 6 mice and expressed as mean ± SD. *P < 0.05; **P < 0.01.